Developer docs
API playgroundTry for free, no card

Search company profiles

Within3

Full company profile

uuid00006nx

Namestring
Within3
Legal namestring
Within3, Inc.
Websiteurl
within3.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Within3 is a privately held SaaS company founded in 2007 and headquartered in Lakewood/Westlake, Ohio, that provides an AI-supported insights management platform for the life sciences industry. Its flagship product, the Launch Intelligence Platform, unifies field insights, healthcare professional (HCP) and key opinion leader (KOL) engagement, social listening across 800+ digital channels, claims and clinical trial data, scientific publications, and real-world data into a single decision-ready view aimed at pharmaceutical product launches. Platform capabilities include AI-powered Insights Reporting (proprietary NLP trained on medical language, sentiment, and context), KOL Mapping with network analytics that assess influence beyond publication counts, Virtual Advisory Boards with 40+ engagement applications and an AI Moderator Assistant, Social Listening, and the Dataverse ecosystem integrating EHR, claims, and specialty data partners.

The company targets three primary business units within pharmaceutical and biotech organizations: Medical Affairs (KOL engagement, advisory boards, MSL outreach, publication planning), Commercial (market and competitive intelligence, launch readiness), and Clinical/R&D (trial design, site selection, investigator identification). A fourth segment focuses on Emerging Biotechs and first-time launchers with leaner teams and compressed timelines. The business model is annual subscription SaaS with two disclosed tiers (IMP full platform and IMP Basic entry-level), bundled with dedicated client success teams and professional services; pricing is quote-based and not publicly disclosed. Distribution is primarily direct enterprise field sales supplemented by event-driven demand generation at industry conferences (MAPS EMEA, Fierce Pharma Engage) and content marketing.

Within3 is reported as trusted by all top 20 global pharmaceutical companies and 70+ biotechs, with 70,000+ HCPs and patients engaged on the platform. The company completed a $100 million growth funding round in 2020 led by Insight Partners with Silversmith Capital Partners, acquired Voxx Analytics and rMark Bio in 2021, launched the Dataverse ecosystem in February 2026, and appointed Erin Mistry as CEO in June 2026 to lead the next phase of global commercialization. Headcount is reported in the 251-500 range.

Short descriptiontext

Within3 provides an AI-supported SaaS insights management platform that unifies KOL engagement, social listening, advisory boards, and real-world data to help pharmaceutical and biotech companies accelerate product launches and decision-making.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLakewood, United States
HQ citystring
Lakewood
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical launch intelligence, virtual advisory boards, KOL mapping analytics, life sciences insights management, medical affairs platform
Industry2 codes
PRIMARYHLACAEAJ
Adherence, Reminders & Engagement Automation (Medication/Follow-up)
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
SECONDARYHLALABAJ
Patient Engagement, Education & Messaging Platforms (portal/CRM integrated)
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
NAICS code1 code
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Pharmaceutical Launch Intelligence Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1SaaS Platform Subscription
TypeSubscription Recurring
Description

Annual or multi-year subscription-based access to the Launch Intelligence platform. The platform offers tiered packages (IMP and IMP Basic) with varying levels of features and data sources included. Dedicated client success team included at no extra cost.

within3.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Pricing details2 tiers
1IMP - Full Insights Management Platform with unlimited group engagement applications, AI-powered Moderator Assistant, comprehensive insights reporting with broad data sources including social listening, congress feeds, KOL mapping, and custom data source support.
ModelSubscriptionBilling cadenceAnnual
Notes

Full platform access with unlimited engagement applications, AI Moderator Assistant, 10 Congress Social Feeds with dynamic reporting, and bespoke KOL ID & Mapping with network analytics. Includes all Within3 data sources: group engagement, social listening (800+ sites), global medical congresses, US claims, scientific publications, clinical trials, industry payments.

within3.com
2IMP Basic - Entry-level platform with AI-powered Moderator Assistant and basic insights reporting with limited data sources.
ModelSubscriptionBilling cadenceAnnual
Notes

Entry-level tier with AI-powered Moderator Assistant, basic Insights Reporting with 2 included data sources (group engagement and social listening with 800+ sites), and 3 Congress Social Feeds with dynamic reporting.

within3.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Launch Intelligence Platform
Description

AI-supported insights management platform for life sciences that unifies field insights, stakeholder engagement, social, claims, and market signals.

within3.com
+1 more record
Core offering1 text field

Within3 sells the Launch Intelligence Platform, a subscription-based SaaS system that helps pharmaceutical and biotech companies gather, integrate, and analyze insights from healthcare professionals, key opinion leaders (KOLs), patients, social media, claims data, scientific publications, and clinical trials. The platform enables asynchronous virtual advisory boards, KOL mapping with network analytics, social listening across 800+ sites, AI-supported insights reporting, and a Dataverse ecosystem of real-world data partners to support product launch and stakeholder engagement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 90% reduction in analysis and reporting workload
+6 more records
Product overview1 text field

Within3 offers the Launch Intelligence Platform—a unified, AI-powered insights management system for life science companies. The core platform unifies field insights, HCP engagement, social sentiment, claims data, and market signals. Key platform features include Insights Reporting (AI-supported analysis and actionable insights), KOL Mapping (network analytics for disease communities), Social Listening (monitoring across 800+ digital channels), Virtual Advisory Boards (40+ engagement applications with AI Moderator Assistant), and Dataverse (ecosystem connecting real-world data from EHR, claims, and specialty data partners). The company also provides specialized services including Clinical Trial Investigators & Site Selection, Publication Planning & Guidelines Review, Patient Journey & Referral Analysis, HCP/Expert Mapping & Segmentation, Institutional Analysis, US Prescription Behavior analysis, and Field Force Research & Optimization. Two pricing tiers are offered: IMP (full-featured) and IMP Basic (entry-level). The platform is trusted by all top 20 pharmaceutical companies and 70+ biotechs.

Product and service9 records
1Launch Intelligence Platform
CategoryCore platform
Description

Within3's flagship SaaS platform that unifies field insights, stakeholder engagement, social sentiment, claims data, and market signals into a single decision-ready view for pharma and biotech product launches. Trusted by all top 20 pharmaceutical companies and 70+ biotechs.

2Dataverse
CategoryData ecosystem
Description

Ecosystem that connects the Launch Intelligence platform with select data and insight partners to bring EHR, claims, and specialty real-world data into a unified launch decision-making view. Initial partners include Everybody Eats, KAI Conversations, Primum, Thrivable, and Unite Genomics.

3Clinical Trial Investigators & Site Selection
CategoryConsulting service
Description

Service helping clinical teams identify and connect with influential investigators, map regional expertise and clinical centers, assess investigator performance and patient flow, and gain visibility into KOL research focus and competitor affiliations.

4Publication Planning & Guidelines Review
CategoryConsulting service
Description

Service helping Medical Affairs teams review and analyze recent publications, conference abstracts, and clinical guidelines to surface emerging themes, evidence gaps, and experts driving the conversation, including KOL identification and network mapping.

5Patient Journey & Referral Analysis
CategoryConsulting service
Description

Service mapping relationships between primary care providers, specialists, and treatment centers to reveal referral influencers and shape patient access, using claims data to identify HCPs, referral networks, and patient entry points.

6HCP/Expert Mapping & Segmentation
CategoryConsulting service
Description

Service combining scientific, clinical, and network analytics to map key HCPs and experts by specialty, geography, sponsorship, or scientific expertise, helping identify regional and specialty-specific leaders including emerging influencers post-launch.

7Institutional Analysis
CategoryConsulting service
Description

Service combining claims and scientific data to identify leading institutions (academic, clinical, practice-based) to align global and regional strategies, strengthen key relationships, and accelerate growth through center of excellence identification.

8US Prescription Behavior
CategoryConsulting service
Description

Service leveraging real-world prescription data to identify high-value prescribers, optimize targeting strategies, and measure the true impact of commercial activities on prescription growth, with real-time tracking of prescribing trends.

9Field Force Research & Optimization
CategoryConsulting service
Description

Service delivering data-driven analysis to maximize impact of Medical Affairs and Commercial field forces, building regional call lists, customizing insights for MSLs and field roles, and identifying influential HCPs based on referral networks and patient flow.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Array
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-22
Description

Within3 and Array announced a partnership to set new standards in life science stakeholder engagement. The new alliance aims to revolutionize pharma engagement with unprecedented insights.

within3.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-18
Description

Within3's Dataverse is an invite-only ecosystem of data and insight partners that plug directly into the Launch Intelligence platform. Initial partners include Everybody Eats (commercial analytics), KAI Conversations (conversation intelligence), Primum (cancer point-of-care solutions), Thrivable (patient insights), and Unite Genomics (AI-powered health analytics). The ecosystem brings together partner data, client data, and Within3's own data lake to provide a unified view for launch decision-making.

3Voxx Analytics
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-06-11
Description

Within3 announced acquisition of Voxx Analytics to enhance its offerings for the life science sector. The deal aligns with Within3's product innovation strategy and follows a recent $100 million funding round.

silversmith.com
4Lance Hill
Strategic tierCoreTypeOthers
Description

Lance Hill serves as CEO of Within3, providing strategic direction and leadership for the company's growth and product development initiatives.

within3.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest pure-play life-sciences CRM and commercial platform. Directly comparable in serving top-20 pharma KOL, HCP, and stakeholder engagement workflows, with overlapping buyer personas in Medical Affairs and Commercial.

TypeBroad incumbent
Description

Global clinical research and commercial intelligence incumbent serving the same top-20 pharma customer base. Comparable in clinical and commercial engagement workflows, but at much larger scale and across a broader services portfolio.

TypeDirect peer
Description

Clinical trial technology platform serving pharma and biotech R&D. Comparable in clinical-stakeholder engagement, decentralized trial workflows, and life-sciences buyer base.

4Oracle Health Sciences
TypeBroad incumbent
Description

Clinical trial management and pharmacovigilance suite within Oracle's broader health portfolio. Comparable in life-sciences enterprise software, with deeper platform bundling but less specialization in advisory-board engagement.

TypeBroad incumbent
Description

Horizontal CRM with a healthcare and life-sciences vertical. Comparable in HCP and stakeholder relationship management, but as a generalist platform rather than a purpose-built life-sciences engagement tool.

TypeDirect peer
Description

Life-sciences R&D and safety software vendor with overlapping buyer personas in Medical Affairs and pharmacovigilance. Comparable in mid-market pharma and biotech deal profiles.

TypeDirect peer
Description

Decentralized clinical trial operator with a virtual engagement model. Comparable in remote stakeholder and patient engagement, particularly in clinical-development workflows.

TypeEmerging player
Description

Clinical trial and real-world data platform for sponsors and CROs. Comparable in decentralized trial workflows and life-sciences buyer base, with a younger, AI-forward product.

TypeEmerging player
Description

Healthcare commercial intelligence and analytics platform. Comparable in monetizing proprietary data assets for life-sciences commercial teams, though with a data-licensing rather than workflow model.

TypeEmerging player
Description

Health data connectivity and linking platform serving life sciences and providers. Comparable in building data network effects on top of regulated health data assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Within3

Pharmaceutical Launch Intelligence Softwarewithin3.com

Within3 provides an AI-supported SaaS insights management platform that unifies KOL engagement, social listening, advisory boards, and real-world data to help pharmaceutical and biotech companies accelerate product launches and decision-making.

What Within3 does

Within3 is a privately held SaaS company founded in 2007 and headquartered in Lakewood/Westlake, Ohio, that provides an AI-supported insights management platform for the life sciences industry. Its flagship product, the Launch Intelligence Platform, unifies field insights, healthcare professional (HCP) and key opinion leader (KOL) engagement, social listening across 800+ digital channels, claims and clinical trial data, scientific publications, and real-world data into a single decision-ready view aimed at pharmaceutical product launches. Platform capabilities include AI-powered Insights Reporting (proprietary NLP trained on medical language, sentiment, and context), KOL Mapping with network analytics that assess influence beyond publication counts, Virtual Advisory Boards with 40+ engagement applications and an AI Moderator Assistant, Social Listening, and the Dataverse ecosystem integrating EHR, claims, and specialty data partners.

The company targets three primary business units within pharmaceutical and biotech organizations: Medical Affairs (KOL engagement, advisory boards, MSL outreach, publication planning), Commercial (market and competitive intelligence, launch readiness), and Clinical/R&D (trial design, site selection, investigator identification). A fourth segment focuses on Emerging Biotechs and first-time launchers with leaner teams and compressed timelines. The business model is annual subscription SaaS with two disclosed tiers (IMP full platform and IMP Basic entry-level), bundled with dedicated client success teams and professional services; pricing is quote-based and not publicly disclosed. Distribution is primarily direct enterprise field sales supplemented by event-driven demand generation at industry conferences (MAPS EMEA, Fierce Pharma Engage) and content marketing.

Within3 is reported as trusted by all top 20 global pharmaceutical companies and 70+ biotechs, with 70,000+ HCPs and patients engaged on the platform. The company completed a $100 million growth funding round in 2020 led by Insight Partners with Silversmith Capital Partners, acquired Voxx Analytics and rMark Bio in 2021, launched the Dataverse ecosystem in February 2026, and appointed Erin Mistry as CEO in June 2026 to lead the next phase of global commercialization. Headcount is reported in the 251-500 range.

Within3 firmographics

Firmographics
Name
Within3
Legal name
Within3, Inc.
Website
https://within3.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
Within3 provides an AI-supported SaaS insights management platform that unifies KOL engagement, social listening, advisory boards, and real-world data to help pharmaceutical and biotech companies accelerate product launches and decision-making.
Ownership category
akta.pro rank

Within3 industry classification

Industry
Product category
Pharmaceutical Launch Intelligence Software
NAICS
Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAEAJ
Adherence, Reminders & Engagement Automation (Medication/Follow-up)
Healthcare & Life Sciences/Digital Health & Health IT/Patient Engagement, CRM & Experience Platforms
SECONDARYHLALABAJ
Patient Engagement, Education & Messaging Platforms (portal/CRM integrated)
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)

Keywords

  • Pharmaceutical launch intelligence
  • Virtual advisory boards
  • KOL mapping analytics
  • Life sciences insights management
  • Medical affairs platform

Where Within3 is headquartered

Location

Headquarters

HQ city
Lakewood
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Within3 business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. SaaS Platform Subscription: Annual or multi-year subscription-based access to the Launch Intelligence platform. The platform offers tiered packages (IMP and IMP Basic) with varying levels of features and data sources included. Dedicated client success team included at no extra cost.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualIMP - Full Insights Management Platform with unlimited group engagement applications, AI-powered Moderator Assistant, comprehensive insights reporting with broad data sources including social listening, congress feeds, KOL mapping, and custom data source support.
SubscriptionAnnualIMP Basic - Entry-level platform with AI-powered Moderator Assistant and basic insights reporting with limited data sources.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels8 records

Within3 product offering

Product offering

Core offering

Within3 sells the Launch Intelligence Platform, a subscription-based SaaS system that helps pharmaceutical and biotech companies gather, integrate, and analyze insights from healthcare professionals, key opinion leaders (KOLs), patients, social media, claims data, scientific publications, and clinical trials. The platform enables asynchronous virtual advisory boards, KOL mapping with network analytics, social listening across 800+ sites, AI-supported insights reporting, and a Dataverse ecosystem of real-world data partners to support product launch and stakeholder engagement.

Product overview

Within3 offers the Launch Intelligence Platform—a unified, AI-powered insights management system for life science companies. The core platform unifies field insights, HCP engagement, social sentiment, claims data, and market signals. Key platform features include Insights Reporting (AI-supported analysis and actionable insights), KOL Mapping (network analytics for disease communities), Social Listening (monitoring across 800+ digital channels), Virtual Advisory Boards (40+ engagement applications with AI Moderator Assistant), and Dataverse (ecosystem connecting real-world data from EHR, claims, and specialty data partners). The company also provides specialized services including Clinical Trial Investigators & Site Selection, Publication Planning & Guidelines Review, Patient Journey & Referral Analysis, HCP/Expert Mapping & Segmentation, Institutional Analysis, US Prescription Behavior analysis, and Field Force Research & Optimization. Two pricing tiers are offered: IMP (full-featured) and IMP Basic (entry-level). The platform is trusted by all top 20 pharmaceutical companies and 70+ biotechs.

Differentiator

Problem solved

Functional benefit

Brands

  • Launch Intelligence Platform: AI-supported insights management platform for life sciences that unifies field insights, stakeholder engagement, social, claims, and market signals.
  • Dataverse

Products and services

  • Launch Intelligence Platform Within3's flagship SaaS platform that unifies field insights, stakeholder engagement, social sentiment, claims data, and market signals into a single decision-ready view for pharma and biotech product launches. Trusted by all top 20 pharmaceutical companies and 70+ biotechs.
  • Dataverse Ecosystem that connects the Launch Intelligence platform with select data and insight partners to bring EHR, claims, and specialty real-world data into a unified launch decision-making view. Initial partners include Everybody Eats, KAI Conversations, Primum, Thrivable, and Unite Genomics.
  • Clinical Trial Investigators & Site Selection Service helping clinical teams identify and connect with influential investigators, map regional expertise and clinical centers, assess investigator performance and patient flow, and gain visibility into KOL research focus and competitor affiliations.
  • Publication Planning & Guidelines Review Service helping Medical Affairs teams review and analyze recent publications, conference abstracts, and clinical guidelines to surface emerging themes, evidence gaps, and experts driving the conversation, including KOL identification and network mapping.
  • Patient Journey & Referral Analysis Service mapping relationships between primary care providers, specialists, and treatment centers to reveal referral influencers and shape patient access, using claims data to identify HCPs, referral networks, and patient entry points.
  • HCP/Expert Mapping & Segmentation Service combining scientific, clinical, and network analytics to map key HCPs and experts by specialty, geography, sponsorship, or scientific expertise, helping identify regional and specialty-specific leaders including emerging influencers post-launch.
  • Institutional Analysis Service combining claims and scientific data to identify leading institutions (academic, clinical, practice-based) to align global and regional strategies, strengthen key relationships, and accelerate growth through center of excellence identification.
  • US Prescription Behavior Service leveraging real-world prescription data to identify high-value prescribers, optimize targeting strategies, and measure the true impact of commercial activities on prescription growth, with real-time tracking of prescribing trends.
  • Field Force Research & Optimization Service delivering data-driven analysis to maximize impact of Medical Affairs and Commercial field forces, building regional call lists, customizing insights for MSLs and field roles, and identifying influential HCPs based on referral networks and patient flow.

Quantifiable outcome

  • 90% reduction in analysis and reporting workload
  • +6 more outcomes

Companies that use Within3

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Within3 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability9 records

Feature5 records

Within3 partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and strategic.

  • ArrayflagshipStrategic or Co-development Partner · 22 June 2026Within3 and Array announced a partnership to set new standards in life science stakeholder engagement. The new alliance aims to revolutionize pharma engagement with unprecedented insights.
  • Dataverse Ecosystem PartnerscoreTechnology or Integration · 18 February 2026Within3's Dataverse is an invite-only ecosystem of data and insight partners that plug directly into the Launch Intelligence platform. Initial partners include Everybody Eats (commercial analytics), KAI Conversations (conversation intelligence), Primum (cancer point-of-care solutions), Thrivable (patient insights), and Unite Genomics (AI-powered health analytics). The ecosystem brings together partner data, client data, and Within3's own data lake to provide a unified view for launch decision-making.
  • Voxx AnalyticsstrategicStrategic or Co-development Partner · 11 June 2021Within3 announced acquisition of Voxx Analytics to enhance its offerings for the life science sector. The deal aligns with Within3's product innovation strategy and follows a recent $100 million funding round.
  • Lance HillcoreOthersLance Hill serves as CEO of Within3, providing strategic direction and leadership for the company's growth and product development initiatives.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Within3 competitors and assessment

Company assessment

Direct peers

  • Veeva Systems: Largest pure-play life-sciences CRM and commercial platform. Directly comparable in serving top-20 pharma KOL, HCP, and stakeholder engagement workflows, with overlapping buyer personas in Medical Affairs and Commercial.
  • Medidata Solutions (Dassault Systèmes): Clinical trial technology platform serving pharma and biotech R&D. Comparable in clinical-stakeholder engagement, decentralized trial workflows, and life-sciences buyer base.
  • ArisGlobal: Life-sciences R&D and safety software vendor with overlapping buyer personas in Medical Affairs and pharmacovigilance. Comparable in mid-market pharma and biotech deal profiles.
  • Science 37: Decentralized clinical trial operator with a virtual engagement model. Comparable in remote stakeholder and patient engagement, particularly in clinical-development workflows.

Broad incumbents

  • IQVIA: Global clinical research and commercial intelligence incumbent serving the same top-20 pharma customer base. Comparable in clinical and commercial engagement workflows, but at much larger scale and across a broader services portfolio.
  • Oracle Health Sciences: Clinical trial management and pharmacovigilance suite within Oracle's broader health portfolio. Comparable in life-sciences enterprise software, with deeper platform bundling but less specialization in advisory-board engagement.
  • Salesforce Health Cloud: Horizontal CRM with a healthcare and life-sciences vertical. Comparable in HCP and stakeholder relationship management, but as a generalist platform rather than a purpose-built life-sciences engagement tool.

Emerging players

  • Castor: Clinical trial and real-world data platform for sponsors and CROs. Comparable in decentralized trial workflows and life-sciences buyer base, with a younger, AI-forward product.
  • Definitive Healthcare: Healthcare commercial intelligence and analytics platform. Comparable in monetizing proprietary data assets for life-sciences commercial teams, though with a data-licensing rather than workflow model.
  • Datavant: Health data connectivity and linking platform serving life sciences and providers. Comparable in building data network effects on top of regulated health data assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Within3 social profiles

Digital presence

Within3 compliance and trust

Trust signal

Compliance1 record

Within3 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Within3 leadership team

Management profile

Number of profiles

Profiles6 records

Within3 funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Within3 M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Within3

What does Within3 do?

Within3 sells the Launch Intelligence Platform, a subscription-based SaaS system that helps pharmaceutical and biotech companies gather, integrate, and analyze insights from healthcare professionals, key opinion leaders (KOLs), patients, social media, claims data, scientific publications, and clinical trials. The platform enables asynchronous virtual advisory boards, KOL mapping with network analytics, social listening across 800+ sites, AI-supported insights reporting, and a Dataverse ecosystem of real-world data partners to support product launch and stakeholder engagement.

Is Within3 a public or private company?

Within3 is a private company. It is classified as venture growth investor backed and is currently operating.

When was Within3 founded?

Within3 was founded in 2007. It employs 51 to 100 people.

Where is Within3 based?

Within3 is headquartered in Lakewood, United States, in the North America region.

How does Within3 make money?

One revenue line is on record: saaS Platform Subscription.

Who are Within3's main competitors?

Direct peers on record are Veeva Systems, Medidata Solutions (Dassault Systèmes), ArisGlobal and Science 37. Broad incumbents are IQVIA, Oracle Health Sciences and Salesforce Health Cloud. Emerging players are Castor, Definitive Healthcare and Datavant.

Does Within3 have an API?

No public API is recorded for Within3.

What industry is Within3 in?

Within3's product category is Pharmaceutical Launch Intelligence Software. Its primary akta.pro industry code is HLACAEAJ, Adherence, Reminders & Engagement Automation (Medication/Follow-up), with a secondary code of HLALABAJ, Patient Engagement, Education & Messaging Platforms (portal/CRM integrated). Its NAICS code is 513210 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Within3: Ira Daly Named Chief Operating Officer To Lead Commercial GrowthWithin3 appointed Ira Daly as chief operating officer to lead commercial growth, client success, and strategic partnerships. Daly brings over 18 years at IQVIA, most recently as senior vice president of offering development. He will focus on expanding relationships with emerging biotechnology companies and global pharmaceutical organizations.citybizWithin3 Names Former IQVIA Executive Ira Daly Chief Operating OfficerWithin3 appointed Ira Daly as chief operating officer, overseeing business development, client success, and strategic partnerships. Daly brings over 18 years of experience at IQVIA, most recently as senior vice president of offering development. He will focus on expanding relationships with emerging biotechnology companies and global pharmaceutical manufacturers.Business Wire BlogWithin3 Appoints Ira Daly as Chief Operating OfficerWithin3 appointed Ira Daly as Chief Operating Officer, bringing nearly two decades of biopharma business development experience from IQVIA. Daly will lead business development, client success, and strategic partnerships, focusing on scaling partnerships with emerging biotechs and global pharma.FinancialContent Business PageWithin3 Appoints Ira Daly as Chief Operating OfficerWithin3 appointed Ira Daly as Chief Operating Officer, bringing nearly two decades of biopharma business development experience from IQVIA. Daly will lead business development, client success, and strategic partnerships, focusing on scaling partnerships with emerging biotechs and global pharma.FiercePharmaFrom Data Rich to Decision Ready in Life SciencesWithin3 executives Erin Mistry and Ian McKinnon discuss how life sciences organizations face decision delays despite data availability, citing silos and unclear accountability. They examine sharing insights across teams and balancing compliance with speed, and note AI's growing role while emphasizing human judgment.FinancialContent Business PageWithin3 Appoints Erin Mistry as Chief Executive OfficerWithin3 announced the appointment of Erin Mistry as Chief Executive Officer, effective immediately. Mistry brings more than 20 years of experience in global biopharma commercialization, having launched and priced over 20 pharmaceutical products across eight therapeutic areas, most recently serving as Chief Commercial Officer at CorMedix where she drove the company to profitability within a year of launching DefenCath. As CEO, Mistry will lead the expansion of Within3's Launch Intelligence platform, helping pharmaceutical teams unify fragmented data and accelerate product launches.American City Business JournalsWithin3 hires Erin Mistry as CEO, founder Lance Hill exitsWithin3 hired Erin Mistry as CEO, replacing founder Lance Hill, who left in May. Mistry previously launched over 20 pharmaceutical products across eight therapeutic areas. She will drive expansion of the company's Launch Intelligence platform.Business Wire BlogWithin3 Introduces Dataverse to Expand Real-World Data Coverage for Pharma Launch IntelligenceWithin3, a Cleveland-based pharmaceutical technology company, announced Dataverse, an ecosystem that expands its Launch Intelligence platform by integrating real-world data sources including electronic health records, claims, and specialty data from partner organizations. The platform launches with five data partners—Everybody Eats, Kai Conversations, Unite, PRiMUM, and Thrivable—to help pharmaceutical teams reduce blind spots throughout the product launch lifecycle. Within3 states the platform is designed to provide a comprehensive data picture for commercial, medical, and clinical teams, addressing the challenge that pharma companies lose on execution rather than innovation.PharmiWeb.comWithin3 Introduces Dataverse to Expand Real-World Data Coverage for Pharma Launch IntelligenceWithin3, a Cleveland-based pharma launch intelligence platform provider, announced the launch of Dataverse, an invite-only ecosystem that integrates multiple real-world data sources including electronic health records, claims, and specialty data from five inaugural partner companies. The platform aims to help pharmaceutical companies reduce blind spots throughout the product launch lifecycle by providing a unified, governed data environment for commercial, medical, and clinical teams. The five launch partners include Everybody Eats, Kai Conversations, Unite, PRiMUM, and Thrivable, each contributing distinct data capabilities to the ecosystem.Within3Launch excellence requires Launch Intelligence™The article outlines a framework for 'Launch Intelligence' designed to help pharmaceutical companies improve the success rates of new drug launches by addressing common pitfalls such as lack of actionable insights and regulatory hurdles. It details nine strategic steps, including cross-functional collaboration, real-time market intelligence, and patient-centric engagement, often leveraging technology platforms like Within3's Launch Intelligence™. The piece cites industry data indicating that a significant portion of pharmaceutical launches miss sales targets, emphasizing the need for adaptive, data-driven strategies.